Noxopharm Ltd
Noxopharm Studies Confirm Cancer-Fighting Potential of Sofra Platform
Noxopharm data show Sofra's TLR8-boosting oligonucleotides could amplify cancer immunotherapy; US patent backing strengthens breakthrough potential.
Noxopharm SOF-SKN Data Shows Prolonged Skin Retention with Minimal Systemic Absorption
Noxopharm's SOF-SKN shows 3.5-day skin retention, minimal systemic absorption in preclinical tests, guiding dosing regimens and regulatory filings.
Noxopharm Advances HERACLES Trial as Sofra Platform Gains US Momentum
Noxopharm (ASX: NOX) has successfully completed the second dosing cohort in its first-in-human HERACLES trial for novel autoimmune drug candidate SOF-SKN. The safety steering committee confirmed the dose level was safe and tolerable, enabling the study to progress to a higher concentration in the next cohort. The company also reported promising preclinical results from a […]
Noxopharm advances Chroma drug platform to target glioblastoma and leukaemia
Noxopharm (ASX: NOX) has made ‘substantial progress’ with its Chroma technology platform, reporting encouraging brain cancer results and early work on leukaemia. The Chroma drug development program focuses on generating first-in-class novel cancer treatment options in areas of substantial unmet need to create future commercial opportunities for the company. Glioblastoma – a lethal and incurable […]